Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Type 2 diabetes
Advertisement
Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech
SEOUL, South Korea, August 24, 2026 Hanmi Pharm announced an exclusive global licensing agreement with Genentech, a member of...
Eli Lilly Escalates Fight Against Illegal Retatrutide Market
INDIANAPOLIS, Indiana, August 12, 2026 Eli Lilly and Company has intensified its efforts to combat the illegal sale of...
Novo Nordisk Launches Once-Weekly Awiqli in the U.S.
Plainsboro, New Jersey, August,11, 2026 Novo Nordisk has announced the nationwide U.S. launch of Awiqli® (insulin icodec-abae) injection 700...
Aqua Medical Appoints Bob Haggerty to Lead Diabetes Growth
Pleasanton, California, August 4, 2026 Aqua Medical, Inc. has announced the appointment of Robert “Bob” Haggerty as President and...
Advertisements
Aqua Medical Treats First U.S. Patient in Diabetes Trial
PLEASANTON, Calif., July 28, 2026 Aqua Medical, Inc. has achieved a major clinical milestone with the successful treatment of...
Antag Therapeutics Doses First Patient in Phase 2a Trial of AT7687
COPENHAGEN, Denmark, July 28, 2026 Antag Therapeutics announced that the first patient has been dosed in its Phase 2a...
Par Health Launchs First FDA-Approved Generic Janumet® XR in U.S.
ST. LOUIS – July 24, 2026 Par Health, Inc. has announced the U.S. launch of its generic version of...
Eli Lilly Reports Positive Phase 3 Retatrutide Results
INDIANAPOLIS, July 23, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3 TRIUMPH-2 and...
Dexcom Selected as First Participant in FDA TEMPO Pilot Program
San Diego, July 22, 2026 Dexcom announced that it has become the first company selected by the U.S. Food...
Advertisement
